Catalyst
Slingshot members are tracking this event:
Immunomedics (IMMU) to Complete Phase 3 Pivotal Trial Preparation for IMMU-132 in Metastatic Triple-Negative Breast Cancer in 2H 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2017
Occurred Source:
http://www.immunomedics.com/pdfs/news/2017/PR01182017a.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Pivotal Trial, Trial Preparation, Immu-132, Metastatic Triple-negative Breast Cancer, 2h 2016
